The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...

The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line ...

ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer ...

Navigate HR+/HER2- metastatic breast cancer treatment by knowing which questions to ask your doctor about progression, next therapies, clinical trials, and quality of life.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved additional ...

Enhertu plus Perjeta is the first new first-line treatment for HER2-positive breast cancer in over a decade, approved by the ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

But having treated breast cancer and seeing the drug development, I think people with Her2-positive breast cancer should be encouraged to know that we have drugs that increase the cure rate ...

HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. In about 1 of every ...

The FDA approved fam-trastuzumab derextecan-nki (Enhertu; Daiichi Sankyo, Inc), a HER2-directed antibody-drug conjugate (ADC), in combination with pertuzumab as a first-line treatment for patients ...

Elissa Kalver was 34 when she found a lump in her breast. She had no family history of cancer and had just welcomed her first child. She assumed the lump was a cyst. But when she went to get it ...

To break it down: The first part of the name, HER2, stands for “human epidermal growth factor receptor 2.” This refers to a protein found on the surface of breast cells that helps direct how quickly ...